Crispr Therapeutics AG, of Basel, Switzerland, and contract development and manufacturing organization Masthercell SA said they signed a deal to develop and manufacture allogeneic CAR T therapies. Mastercell will be responsible for the development and cGMP manufacturing of CTX-101 for use in clinical studies. CTX-101 is in development by Crispr for the treatment of CD19-positive malignancies.